Skip to content

Self-controlled clinical trial of functionalized hyaluronic acid to reduce postoperative scar

Self-controlled clinical trial of functionalized hyaluronic acid to reduce postoperative scar

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122219
Enrollment
Unknown
Registered
2026-04-10
Start date
2026-04-14
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pathological scar

Interventions

Wendesilin Hyaluronic Acid Hydrogel Treatment Group:Local application of Wendesilin sodium hyaluronate hydrogel bio-glue

Sponsors

Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 14 to 65 years (including 14 years, but excluding 65 years), and in good health. 2. Patients who undergo the following surgical treatments in our hospital and meet the corresponding criteria: A. pathological scar excision surgery (scar length =4 cm); B. split-thickness skin graft donor site (donor area >20 cm²). 3. Patients with complete preoperative data, mainly including standard preoperative photographs, demographic data, and disease-related data. 4. Patients who have read and signed the informed consent form before the start of the study.

Exclusion criteria

Exclusion criteria: 1. Patients who are unable to complete effective follow-up due to various reasons. 2. Patients who receive additional interventions during the postoperative follow-up period that may affect scar healing outcomes, including reoperation other than that required for the management of complications; radiotherapy; local intralesional scar injection therapy; and other interventions that may significantly affect scar formation. 3. Patients with pre-existing arteriovenous disease, neoplastic disease, excessively large pathological scars, or scars crossing joints. 4. Patients with a previous definite diagnosis of keloid or with typical clinical manifestations of keloid.

Design outcomes

Primary

MeasureTime frame
Recurrence rate of pathological scars within 12 months postoperatively;

Secondary

MeasureTime frame
Patient Scar Assessment Scale (PSAS) score;Observer Scar Assessment Scale (OSAS) score;

Countries

China

Contacts

Public ContactPeiru Min

Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital

aru_ren@msn.com+86 136 0167 1271

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026